Biologic Excipient Market Size was estimated at 6.59 (USD Billion) in 2022.The Biologic Excipient Market Industry is expected to grow from 7.63(USD Billion) in 2023 to 28.79 (USD Billion) by 2032. The Biologic Excipient Market CAGR (growth rate) is expected to be around 15.9% during the forecast period (2024 - 2032).
Advancements in biopharmaceutical engineering techniques have led to the increasing demand for biologics, such as monoclonal antibodies, vaccines, and therapeutic proteins. Biologic excipients play a crucial role in stabilizing biologics during formulation, storage, and delivery. The rising prevalence of chronic diseases and the increasing demand for personalized medicine are key drivers of the biologic excipient market.Recent trends in the market include a growing focus on biocompatibility, sustainability, and cost-effectiveness of biologic excipients. There is a shift towards using plant-based and animal-free excipients to meet the increasing demand for vegan and cruelty-free products. Additionally, the development of novel excipients with enhanced functionalities, such as extended release and targeted delivery, is creating new opportunities for market growth.
Source Primary Research, Secondary Research, MRFR Database and Analyst Review
The increasing prevalence of chronic diseases, such as cancer, autoimmune disorders, and diabetes, has led to a growing demand for biologics. Biologics are complex molecules derived from living organisms that have therapeutic properties. They are used to treat a wide range of diseases, including cancer, rheumatoid arthritis, and Crohn's disease. The increasing adoption of biologics is expected to drive the growth of the biologic excipient market over the forecast period. The development of new biologics and the expansion of existing biologics into new therapeutic areas are also contributing to the growth of the market.For instance, the approval of new cancer immunotherapies and the expansion of biologics for the treatment of autoimmune diseases are expected to drive the demand for biologic excipients. Additionally, the increasing use of biologics in combination therapies is further boosting the market growth. The growing adoption of biologics in emerging markets is another key factor driving the growth of the biologic excipient market. Emerging markets, such as China and India, represent a significant growth opportunity for the market.The increasing healthcare expenditure and the rising prevalence of chronic diseases in these regions are expected to drive the demand for biologics and, consequently, the demand for biologic excipients.
The development of new and innovative excipients is essential for the advancement of the biologics industry. Biologic excipients play a critical role in ensuring the stability, efficacy, and safety of biologics. Technological advancements in excipient development have led to the development of excipients that are more effective, more stable, and more compatible with biologics. For instance, the development of novel excipients that can improve the solubility and stability of biologics has enabled the development of new and more effective biologics.Additionally, the development of excipients that can target specific delivery mechanisms has improved the efficacy of biologics. The increasing focus on patient-centric drug development is also driving the demand for excipients that can improve the safety and tolerability of biologics. Ongoing research and development in the field of biologic excipients are expected to further drive the growth of the biologic excipient market. The development of new excipients with improved properties and functionalities is expected to support the development of new and more effective biologics, thereby driving the growth of the market.
Government policies and regulations play a significant role in shaping the growth of the biologic excipient market. Supportive government policies and a favorable regulatory landscape can encourage investment in research and development and promote the adoption of biologics and biologic excipients. For instance, the increasing focus on biosimilars and the development of biosimilar pathways in various countries is expected to drive the growth of the biologic excipient market.Biosimilars are similar to biologics but are developed and manufactured by different companies. The development of biosimilars has increased the availability and affordability of biologics, thereby driving the demand for biologic excipients. Additionally, government initiatives to support the development and manufacturing of biologics in emerging markets are expected to further drive the growth of the biologic excipient market. The increasing focus on healthcare infrastructure development and the growing awareness of biologics in emerging markets are expected to create favorable conditions for the growth of the market.
Source Segment Insight and Overview The biologic excipient market is segmented based on source into animal-derived, human-derived, and recombinant. Among these segments, the recombinant segment is expected to witness the fastest growth over the forecast period. The growth of this segment can be attributed to the increasing adoption of recombinant DNA technology for the production of biologics. Recombinant excipients offer several advantages over animal-derived and human-derived excipients, such as reduced risk of contamination, improved consistency, and scalability.The animal-derived segment accounted for the largest share of the biologic excipient market in 2023. However, its share is expected to decline over the forecast period due to the growing concerns over the use of animal-derived products in the pharmaceutical industry. The human-derived segment is expected to witness moderate growth over the forecast period. The growth of this segment can be attributed to the increasing demand for human-derived excipients in the production of biologics for therapeutic applications. Human-derived excipients are considered to be safer and more effective than animal-derived excipients.Overall, the biologic excipient market is expected to grow at a significant rate over the forecast period. The growth of the market can be attributed to the increasing demand for biologics for the treatment of various diseases.
Source Primary Research, Secondary Research, MRFR Database and Analyst Review
Form Segment Insight and Overview The Biologic Excipient Market is segmented based on form into liquid, powder, and gel. Among these, the liquid form segment is expected to hold the largest share of the market in 2023, and it is projected to continue its dominance throughout the forecast period. The growth of this segment can be attributed to the ease of handling and administration of liquid excipients, as well as their ability to be easily incorporated into various drug formulations. The powder form segment is expected to witness a steady growth rate during the forecast period, owing to its stability and cost-effectiveness.The gel form segment is anticipated to gain traction due to its ability to provide sustained release of drugs and its use in topical applications.
Stabilizers, Emulsifiers and Preservatives are the key function segments in the Biologic Excipient Market. Stabilizers help maintain the stability and integrity of biologics during storage and transportation. Emulsifiers facilitate the formation of stable emulsions, while Preservatives prevent microbial growth and contamination. The Biologic Excipient Market for Stabilizers is projected to reach USD 12.45 billion by 2028, growing at a CAGR of 14.3%. The Emulsifier segment is expected to grow to USD 9.87 billion by 2028, with a CAGR of 13.5%.The Preservative segment is estimated to reach USD 6.23 billion by 2028, exhibiting a CAGR of 12.7%. These segments are driven by the increasing demand for biologics in various therapeutic applications, such as oncology, immunology, and gene therapy.
Vaccines, Protein Therapeutics, and Monoclonal Antibodies are the major end-use applications of biologic excipients. The Biologic Excipient Market revenue from Vaccines segment is projected to grow from USD 2.34 Billion in 2023 to USD 7.21 Billion by 2032, at a CAGR of 15.2%. Protein Therapeutics segment is estimated to be valued at USD 3.56 Billion in 2023 and is projected to reach USD 11.23 Billion by 2032, exhibiting a CAGR of 15.4%. Monoclonal Antibodies segment is anticipated to grow from USD 1.73 Billion in 2023 to USD 5.35 Billion by 2032, registering a CAGR of 15.6%.The growth of these segments is attributed to the increasing prevalence of chronic diseases, technological advancements in biologics manufacturing, and rising demand for personalized medicine.
The regional segmentation of the Biologic Excipient Market offers insights into the market's geographic distribution and growth patterns. North America holds a dominant position in the market, accounting for a significant share of the Biologic Excipient Market revenue. The presence of major pharmaceutical and biotechnology companies, advanced healthcare infrastructure, and a high demand for biologics drive growth in this region. Europe is another key market, with a strong pharmaceutical industry and a growing focus on biologics development.The APAC region is expected to witness substantial growth in the coming years, driven by increasing healthcare spending, rising prevalence of chronic diseases, and government initiatives to promote biologics adoption. South America and MEA are emerging markets with potential for growth, as they experience increasing demand for biologics and expanding healthcare systems.
Source Primary Research, Secondary Research, MRFR Database and Analyst Review
Major players in Biologic Excipient Market industry are constantly developing and enhancing their product offerings to meet the evolving needs of the market. Leading Biologic Excipient Market players are focusing on research and development to introduce innovative and advanced biologic excipients. The Biologic Excipient Market development is driven by increasing demand for biologics and biopharmaceuticals, growing adoption of biologics in various therapeutic areas, and supportive government regulations. The Biologic Excipient Market Competitive Landscape is characterized by a mix of established players and emerging companies.Pfizer is a leading player in the Biologic Excipient Market and a pharmaceutical company. They offer a range of biologic excipients, including cell culture media, serum-free media, and protein purification reagents. Pfizer has a strong focus on research and development and is committed to providing innovative and high-quality products to its customers.Samsung Biologics is a leading competitor in the Biologic Excipient Market and a contract development and manufacturing organization. They provide a range of biologic excipient services, including cell line development, bioprocess optimization, and fill and finish. Samsung Biologics has a strong track record of success and is known for its high-quality products and services.
Key Companies in the Biologic Excipient Market Include
The biologic excipient market size was valued at USD 7.63 billion in 2023 and is projected to reach USD 28.79 billion by 2032, exhibiting a CAGR of 15.9% during the forecast period. The market growth is attributed to rising demand for biologics, increasing prevalence of chronic diseases, and technological advancements in the pharmaceutical industry.
Key industry developments include In 2023, Lonza announced the expansion of its biologics excipient manufacturing facility in Portsmouth, New Hampshire, to meet the growing demand for high-quality excipients. In 2022, Merck KGaA launched a new range of excipients specifically designed for biologics, offering enhanced stability and functionality. Several biopharmaceutical companies are collaborating with excipient manufacturers to develop innovative excipients that address specific challenges in biologic drug development and manufacturing.
| Report Attribute/Metric | Details |
| Market Size 2022 | 6.59(USD Billion) |
| Market Size 2023 | 7.63(USD Billion) |
| Market Size 2032 | 28.79(USD Billion) |
| Compound Annual Growth Rate (CAGR) | 15.9% (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Evonik Industries, Cargill, Roquette, Archer Daniels Midland Company, Lonza, Ingredion Incorporated, CP Kelco, Kerry Group, Ashland, Kerry Ingredients, DowDuPont, Novozymes, FMC Corporation, DSM, Tate Lyle |
| Segments Covered | Source, Form, Function, End-Use Application, Regional |
| Key Market Opportunities | Increasing demand for biologics Advancements in biotechnology Growing prevalence of chronic diseases Rising focus on biocompatibility Expansion of biosimilar and generic biologics market |
| Key Market Dynamics | Growing demand for biologics Advancements in biotechnology Rising adoption of biosimilars Increasing focus on biodegradability Regulatory incentives |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Biologic Excipient Market is expected to reach USD 28.79 billion by 2032, growing at a CAGR of 15.9% from 2024 to 2032.
North America is expected to hold the largest market share in the Biologic Excipient Market, accounting for over 40% of the market in 2023.
The key growth drivers of the Biologic Excipient Market include increasing demand for biologics, technological advancements, and growing investment in biopharmaceutical research and development.
Biologic Excipients are primarily used in the formulation of therapeutic proteins, vaccines, and monoclonal antibodies.
Key competitors in the Biologic Excipient Market include Lonza, MilliporeSigma, Charles River Laboratories, and Thermo Fisher Scientific.
The Biologic Excipient Market is expected to grow at a CAGR of 15.9% from 2024 to 2032.
The challenges faced by the Biologic Excipient Market include regulatory complexities, supply chain disruptions, and competition from synthetic excipients.
Opportunities for growth in the Biologic Excipient Market include increasing demand for biosimilars, advancements in biomanufacturing technologies, and expanding applications in cell and gene therapies.
Technological advancements are driving innovation in the Biologic Excipient Market, leading to the development of new and improved excipients with enhanced functionality and stability.
The regulatory landscape is a key factor influencing the Biologic Excipient Market, as stringent regulations ensure the safety and efficacy of excipients used in biologics.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
